ID   NOY1
AC   CVCL_0P30
SY   NOY-1; Nagoya Ovarian Yolk sac tumor cell line clone 1
DR   BTO; BTO_0005874
DR   Kerafast; ENG101
DR   Wikidata; Q54930934
RX   PubMed=18547965;
RX   PubMed=21150160;
CC   Population: Japanese.
CC   Doubling time: 28 hours (PubMed=18547965).
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
DI   NCIt; C8107; Ovarian yolk sac tumor
DI   ORDO; Orphanet_876; Yolk sac tumor
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_0P31 ! NOY2
SX   Female
AG   28Y
CA   Cancer cell line
DT   Created: 10-04-15; Last updated: 19-12-24; Version: 9
//
RX   PubMed=18547965; DOI=10.1159/000139138;
RA   Shibata K., Kajiyama H., Yamamoto E., Terauchi M., Ino K., Nawa A.,
RA   Kikkawa F.;
RT   "Establishment and characterization of an ovarian yolk sac tumor cell
RT   line reveals possible involvement of Nkx2.5 in tumor development.";
RL   Oncology 74:104-111(2008).
//
RX   PubMed=21150160; DOI=10.1159/000320744;
RA   Shibata K., Umezu T., Sakurai M., Kajiyama H., Yamamoto E., Ino K.,
RA   Nawa A., Kikkawa F.;
RT   "Establishment of cisplatin-resistant ovarian yolk sac tumor cells and
RT   investigation of the mechanism of cisplatin resistance using this cell
RT   line.";
RL   Gynecol. Obstet. Invest. 71:104-111(2011).
//